AI assistant
Sending…
Kezar Life Sciences, Inc. — Director's Dealing 2021
Dec 15, 2021
34845_dirs_2021-12-15_9bc5c285-257b-483d-ad47-4f6b2b1bd2e4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2021-12-14
Reporting Person: Fowler John Franklin (Director, CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-14 | Common Stock | M | 7700 | $0.90 | Acquired | 366904 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-14 | Employee Stock Option (Right to Buy) | $0.90 | M | 7700 | Disposed | 2025-09-09 | Common Stock (7700) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3750 | Indirect |
| Common Stock | 38461 | Indirect |
Footnotes
F1: The reporting person is a member of Montebello Holdings LLC. The reporting person disclaims Section 16 beneficial ownership of the securities held by Montebello Holdings LLC, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F2: Fully vested.
More from Kezar Life Sciences, Inc.
Delisting Announcement
2026
May 11
M&A Activity
2026
May 11
Interim / Quarterly Report
2026
May 11
Annual Report
2026
Apr 30
Legal Proceedings Report
2026
Apr 3
Merger & Acquisition
2026
Mar 30
M&A Activity
2026
Mar 30
Major Shareholding Notification
2026
Feb 9
Major Shareholding Notification
2025
Nov 14
Interim / Quarterly Report
2025
Nov 12